🟢 Solid Biosciences is trading 6.69% up in pre-market

Solid Biosciences is trading 6.69% higher in pre-market at $5.90 on October 19, with no verified new company announcement explaining the rise.

• Search results surfaced reports about an FDA hold on the IGNITE DMD trial, but the event was from 2019, not a new October 2026 catalyst; a company filing confirms the hold was lifted in 2020.
• The supplied sector context has biotech lower, so it does not explain this stock’s move in the same direction.
• No reliable volume or activity-level figure is available in the supplied price data.